Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
Randomised data will be needed to answer lingering questions about DKN-01.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.